Prognostic factors of interstitial lung disease progression at sequential HRCT in anti-synthetase syndrome

[1]  Guochun Wang,et al.  Clinical Profiles and Prognosis of Patients with Distinct Antisynthetase Autoantibodies , 2017, The Journal of Rheumatology.

[2]  A. Mammen,et al.  A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies , 2017, Rheumatology.

[3]  M. Mejía,et al.  Interstitial lung disease and myositis-specific and associated autoantibodies: Clinical manifestations, survival and the performance of the new ATS/ERS criteria for interstitial pneumonia with autoimmune features (IPAF). , 2017, Respiratory medicine.

[4]  J. Ryu,et al.  Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome. , 2016, Respiratory medicine.

[5]  G. Mynarek,et al.  Pulmonary Involvement in the Antisynthetase Syndrome: A Comparative Cross-sectional Study , 2016, The Journal of Rheumatology.

[6]  A. Mirrakhimov.  Antisynthetase syndrome: a review of etiopathogenesis, diagnosis and management. , 2015, Current medicinal chemistry.

[7]  T. Mimori,et al.  Prognostic Significance of Anti-Aminoacyl-tRNA Synthetase Antibodies in Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease: A Retrospective Case Control Study , 2015, PloS one.

[8]  M. Revel,et al.  Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings. , 2015, European journal of radiology.

[9]  Shandra L. Protzko,et al.  An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. , 2013, American journal of respiratory and critical care medicine.

[10]  M. Fujimoto,et al.  Common and Distinct Clinical Features in Adult Patients with Anti-Aminoacyl-tRNA Synthetase Antibodies: Heterogeneity within the Syndrome , 2013, PloS one.

[11]  C. Oddis,et al.  Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients , 2013, Annals of the rheumatic diseases.

[12]  M. Guiguet,et al.  Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. , 2012, Autoimmunity reviews.

[13]  Xin Lu,et al.  Clinical significance of peripheral blood lymphocyte subsets in patients with polymyositis and dermatomyositis , 2012, Clinical Rheumatology.

[14]  O. Decaux,et al.  Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. , 2012, Autoimmunity reviews.

[15]  I. Marie.  Morbidity and Mortality in Adult Polymyositis and Dermatomyositis , 2012, Current Rheumatology Reports.

[16]  V. Limaye,et al.  Clinical heterogeneity and prognostic features of South Australian patients with anti‐synthetase autoantibodies , 2011, Internal medicine journal.

[17]  Yutaka Kawata,et al.  Long-term follow-up high-resolution CT findings in non-specific interstitial pneumonia , 2010, Thorax.

[18]  N. Kaminski,et al.  Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. , 2009, Arthritis and rheumatism.

[19]  N. Müller,et al.  Fleischner Society: glossary of terms for thoracic imaging. , 2008, Radiology.

[20]  R. Domsic,et al.  Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. , 2007, Arthritis and rheumatism.

[21]  M. Humbert,et al.  Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset , 2007, Thorax.

[22]  F. Trotta,et al.  In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease , 2006, Autoimmunity.

[23]  M. Dalakas,et al.  A New Approach to the Classification of Idiopathic Inflammatory Myopathy: Myositis‐Specific Autoantibodies Define Useful Homogeneous Patient Groups , 1991, Medicine.

[24]  F. Miller,et al.  Lymphocyte activation markers in idiopathic myositis: changes with disease activity and differences among clinical and autoantibody subgroups , 1990, Clinical and experimental immunology.

[25]  E. Arsura,et al.  Adverse impact of interstitial pulmonary fibrosis on prognosis in polymyositis and dermatomyositis. , 1988, Seminars in arthritis and rheumatism.

[26]  T. Mimori,et al.  The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis. , 1983, Arthritis and rheumatism.

[27]  M. Reichlin,et al.  Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. , 1980, Arthritis and rheumatism.

[28]  A. Mirrakhimov.  Antisynthetase syndrome: a review of etiopathogenesis, diagnosis and management. , 2015, Current medicinal chemistry.

[29]  M. L. R. D. Christenson,et al.  An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management , 2012 .

[30]  Jeffrey J. Swigris,et al.  Doença pulmonar intersticial relacionada a miosite e a síndrome antissintetase , 2011 .

[31]  A. Bohan,et al.  Polymyositis and dermatomyositis (second of two parts). , 1975, The New England journal of medicine.

[32]  A. Bohan,et al.  Polymyositis and dermatomyositis (first of two parts). , 1975, The New England journal of medicine.